Pharmafile Logo
Pharmafocus logo
Advanced Search

gastrointestinal

Showing 6 posts of 6 posts found.

Research shows neonatal stem cells could be used as treatment for Crohn’s disease

July 31, 2023
Research and Development Crohn’s disease, Gastrointestinal tract, Stem cells, gastrointestinal

Recent studies from the Ann & Robert H Lurie Children’s Hospital in Chicago have discovered that human neonatal cardiac-derived mesenchymal …

News
shire_image_4

Shire gets positive opinion from EMA on rare gastrointestinal disease treatment

May 27, 2016
Medical Communications, Research and Development, Sales and Marketing CHMP, EMA, Revestive, Shire, gastrointestinal, paediatric, short bowel syndrome, treatment

Shire (LSE: SHP) has announced that it has received a positive opinion from the European Medicines Agency’s (EMA) Committee for …

News
ea_pharma

Eisai announces agreement to set up new gastrointestinal speciality company

March 30, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Ajinomoto, Eisai, absorption, acquisition, ea pharma, gastrointestinal, merger, speciality

Eisai (TYO: 4523) and Ajinomoto Co. (TYO: 2802) have announced an agreement to establish a new gastrointestinal speciality pharmaceutical company, …

News
Enterome logo

Takeda and Enterome collaborate on new therapeutics for stomach disorders

January 6, 2016
Research and Development Enterome, Takeda, gastrointestinal, inflammatory bowel syndrome, irritable bowel syndrome

Takeda and Enterome Bioscience have entered a drug discovery collaboration to research and develop potential new therapeutics for disorders including …

News
Shire image

Shire to buy Meritage Pharma

February 25, 2015
Research and Development, Sales and Marketing AbbVie, Meritage Pharma, Shire, eoe, gastrointestinal

Shire has purchased Meritage Pharma, a privately-held company specialising in gastrointestinal and skin diseases for $70 million. The acquisition means …

News

Nycomed files short bowel syndrome treatment

March 28, 2011
Medical Communications Nycomed, Revestive, gastrointestinal

Specialist pharma company Nycomed has submitted a novel bowel disease treatment for assessment by European regulators. The Marketing Authorisation Application …

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024